Date:4/30/2009

2008 March 31, 2009 ASSETS (unaudited) Current assets: Cash and cash equivalents $66,376 $65,518 Short-term investments 50 50 Accounts receivable, net 29,177 21,676 Prepaid income taxes 1,892 1,818 Prepaid expenses and other 2,885 3,285 Deferred income taxes 1,831 1,703 Total current assets 102,211 94,050 Property and equipment, net 29,639 27,105 Goodwill 34,603 34,653 Intangible assets 2,149 2,012 Other assets 520 447 Total assets $169,122 $158,267 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $3,971 $5,153 Accrued expenses 8,140 4,690 Income taxes payable 2,492 805 Current portion of capital lease obligations 43 - Deferred revenues 12,276 12,608 Total current liabilities 26,922 23,256 Deferred rent 2,183 2,296 Deferred income taxes 1,332 1,326 Other liabilities 1,257 1,117 Total liabilities 31,694 27,995 Stockholders' equity: Preferred stock-$10.00 par value, 500,000 shares authorized, none issued and outstanding
'/>"/>

SOURCE eResearchTechnology, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. CryoLife Reports Record First Quarter Revenues of $26.7 Million
2. Caliper Life Sciences Reports First Quarter 2009 Results
3. Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets
4. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
5. Vanda Pharmaceuticals Reports First Quarter 2009 Results
6. Telik Reports Preclinical Results at AACR Annual Meeting
7. PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results
8. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
9. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
10. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
11. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights